Filing Flows › RenovoRx (RNXT) › Q1 2025
RenovoRx (RNXT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
RenovoRx (RNXT) reported revenue of $197K for the first quarter 2025 (Q1 2025).
RenovoRx, Q1 2025: revenue $197K, net loss $2.4M, operating cash flow −$3.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $197K | — | — |
| Operating profit | −$3.1M | — | — |
| Net earnings | −$2.4M | — | — |
| Operating cash flow | −$3.4M | — | — |
What changed
Revenue was $197K in Q1 2025.
Gross margin was 52.3%. Operating costs exceeded revenue by $3.1M, an operating margin of -1578.7%. The quarter ended with a net loss of $2.4M. Non-operating items added $690K, -29% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$3.4M. Non-cash charges added back $1K of depreciation and $288K of share-based compensation. Working capital and other items used $1.2M. Capital expenditures of $2K exceeded it, leaving free cash flow of −$3.4M.
Questions
What was RenovoRx's revenue in the first quarter 2025?
RenovoRx (RNXT) reported revenue of $197K for the first quarter 2025 (Q1 2025).
Source: RenovoRx 10-Q on SEC EDGAR.